Docetaxel vs paclitaxel

docetaxel (HLX02-BC01). The as part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel

taxanes – such as docetaxel, paclitaxel, and nab-paclitaxel. These drugs are commonly used in combination with other chemotherapy drugs, including

The taxoids, paclitaxel (Taxol) and docetaxel (Taxotere), represent a novel class of antineoplastic drugs. Paclitaxel and docetaxel share a similar mechanism of action: the promotion of microtubule assembly and inhibition of microtubule disassembly. The clinical development of paclitaxel was initial

anthracycline drugs such as doxorubicin, pegylated liposomal doxorubicin and epirubicin taxane drugs such as paclitaxel, docetaxel and nab-paclitaxel

While paclitaxel is a natural product, docetaxel is a semisynthetic product. The most frequent dose-limiting toxicities (DLTs) of both paclitaxel and docetaxel

The incidence of peripheral neuropathy was generally low. Cassier et al. reported a higher rate of peripheral neuropathy with paclitaxel than with docetaxel (7.8% with paclitaxel vs. 0% with docetaxel). Kelly et al. reported a slightly higher rate of peripheral neuropathy with docetaxel (4.8%) than with paclitaxel (2.4%).

anthracycline drugs such as doxorubicin, pegylated liposomal doxorubicin and epirubicin taxane drugs such as paclitaxel, docetaxel and nab-paclitaxel

Common chemotherapy drug combinations ; EC. Epirubicin and cyclophosphamide ; Paclitaxel and carboplatin. Paclitaxel and carboplatin ; Docetaxel and carboplatin.

anthracycline drugs such as doxorubicin, pegylated liposomal doxorubicin and epirubicin taxane drugs such as paclitaxel, docetaxel and nab-paclitaxel